Advertisement
Screener

SAREPTA THERAPEUTICS, INC. (SRPT) ROA

Sarepta Therapeutics, Inc. ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Sarepta Therapeutics, Inc. roa for the quarter ending 2026-06-30 was -4.29%, a change of -2.71% year-over-year.
  • Sarepta Therapeutics, Inc. roa for the quarter ending 2026-03-31 was 2.05%, a change of 9.21% year-over-year.
  • Sarepta Therapeutics, Inc. roa for the quarter ending 2025-12-31 was -21.30%, a 458.81% decline year-over-year.
  • Sarepta Therapeutics, Inc. roa for the quarter ending 2025-09-30 was -7.77%, a 329.63% decline year-over-year.
  • Sarepta Therapeutics, Inc. roa for fiscal 2025 was -21.30%, a 458.81% decline from fiscal 2024.
  • Sarepta Therapeutics, Inc. roa for fiscal 2024 was 5.94%, a change of 22.35% from fiscal 2023.
  • Sarepta Therapeutics, Inc. roa for fiscal 2023 was -16.42%, a change of 6.07% from fiscal 2022.
  • Sarepta Therapeutics, Inc. roa for fiscal 2022 was -22.49%, a change of -9.18% from fiscal 2021.
Available history
2010-12-31 to 2026-06-30
Data captured

Historical ROA

DateROANet income 12 monthNet income 3 monthTotal assets
2026-06-30-4.29%-$136.73M-$4.89M$3.19B
2026-03-312.05%$65.06M$330.96M$3.18B
2025-12-31-21.30%-$713.41M-$412.23M$3.35B
2025-09-30-7.77%-$271.51M-$50.57M$3.49B
2025-06-30-1.57%-$57.96M$196.89M$3.68B
2025-03-31-7.17%-$248.39M-$447.51M$3.47B
2024-12-315.94%$235.24M$159.05M$3.96B
2024-09-303.38%$121.85M$33.61M$3.6B
2024-06-301.38%$47.3M$6.46M$3.42B
2024-03-310.52%$16.9M$36.12M$3.22B
2023-12-31-16.42%-$535.98M$45.66M$3.26B
2023-09-30-22.22%-$690.88M-$40.94M$3.11B
2023-06-30-29.04%-$907.68M-$23.94M$3.13B
2023-03-31-36.45%-$1.12B-$516.75M$3.06B
2022-12-31-22.49%-$703.49M-$109.24M$3.13B
2022-09-30-22.69%-$716.23M-$257.74M$3.16B
2022-06-30-16.91%-$506.63M-$231.48M$3B
2022-03-31-11.67%-$356.56M-$105.03M$3.06B
2021-12-31-13.30%-$418.78M-$121.98M$3.15B
2021-09-30-18.26%-$486.12M-$48.14M$2.66B
2021-06-30-23.00%-$634.47M-$81.41M$2.76B
2021-03-31-25.45%-$703.89M-$167.25M$2.77B
2020-12-31-18.57%-$554.13M-$189.32M$2.98B
2020-09-30-21.60%-$600.51M-$196.50M$2.78B
2020-06-30-18.40%-$530.34M-$150.82M$2.88B
2020-03-31-22.25%-$655.92M-$17.49M$2.95B
2019-12-31-39.23%-$715.08M-$235.70M$1.82B
2019-09-30-36.43%-$620.27M-$126.33M$1.7B
2019-06-30-32.63%-$570.33M-$276.40M$1.75B
2019-03-31-20.53%-$403.2M-$76.64M$1.96B
2018-12-31-22.04%-$361.92M-$140.90M$1.64B
2018-09-30-20.71%-$245.02M-$76.39M$1.18B
2018-06-30-17.35%-$216.36M-$109.27M$1.25B
2018-03-31-13.08%-$170.14M-$35.36M$1.3B
2017-12-31-3.88%-$50.69M-$24.00M$1.31B
2017-09-30-14.39%-$115.14M-$47.73M$800.28M
2017-06-30-27.58%-$124.15M-$63.05M$450.14M
2017-03-31-24.12%-$123.41M$84.09M$511.53M
2016-12-31-63.02%-$267.27M-$88.45M$424.1M
2016-09-30-49.97%-$243.49M-$56.74M$487.31M
2016-06-30-116.97%-$238.69M-$62.30M$204.07M
2016-03-31-102.29%-$218.24M-$59.77M$213.36M
2015-12-31-80.37%-$220.03M-$64.68M$273.78M
2015-09-30-108.13%-$199.77M-$51.94M$184.75M
2015-06-30-76.41%-$177.05M-$41.85M$231.71M
2015-03-31-69.66%-$169.08M-$61.56M$242.71M
2014-12-31-46.03%-$135.79M-$44.42M$295.03M
2014-09-30-31.40%-$100.19M-$29.23M$319.06M
2014-06-30-33.50%-$113M-$33.87M$337.31M
2014-03-31-35.65%-$98.17M-$28.27M$275.39M
2013-12-31-38.41%-$111.99M-$8.82M$291.57M
2013-09-30-54.27%-$165.23M-$42.03M$304.48M
2013-06-30-94.08%-$172.76M-$19.05M$183.63M
2013-03-31-75.34%-$145.67M-$42.08M$193.34M
2012-12-31-59.17%-$121.29M-$62.07M$204.99M
2012-09-30-114.22%-$60.63M-$49.55M$53.08M
2012-06-30-35.86%-$15.1M$8.04M$42.1M
2012-03-31-46.85%-$21.86M-$17.70M$46.65M
2011-12-31-4.26%-$2.32M-$1.41M$54.37M
2011-09-30-14.00%-$8.55M-$4.02M$61.08M
2011-06-30-15.78%-$11.83M$1.28M$74.93M

Annual ROA

DateROANet income 12 monthTotal assets
2025-12-31-21.30%-$713.41M$3.35B
2024-12-315.94%$235.24M$3.96B
2023-12-31-16.42%-$535.98M$3.26B
2022-12-31-22.49%-$703.49M$3.13B
2021-12-31-13.30%-$418.78M$3.15B
2020-12-31-18.57%-$554.13M$2.98B
2019-12-31-39.23%-$715.08M$1.82B
2018-12-31-22.04%-$361.92M$1.64B
2017-12-31-3.88%-$50.69M$1.31B
2016-12-31-63.02%-$267.27M$424.1M
2015-12-31-80.37%-$220.03M$273.78M
2014-12-31-46.03%-$135.79M$295.03M
2013-12-31-38.41%-$111.99M$291.57M
2012-12-31-59.17%-$121.29M$204.99M
2011-12-31-4.26%-$2.32M$54.37M
2010-12-31-69.99%-$32.18M$45.98M

Similar stocks

Stock NameCountryMarket CapPE Ratio
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
UroGen Pharma Ltd. (URGN)$2.015B-18.42
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
Generate Biomedicines, Inc. (GENB)United States$2.052B
COMPASS Pathways plc (CMPS)$1.812B-4.87
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77